PUK4 A Cost-Comparison Analysis of Treating Overactive Bladder (OAB) With Fesoterodine, Tolterodine or Solifenacin in Daily Clinical Practice in Spain
Abstract
Authors
A. Sicras-Mainar J. Rejas R. Navarro-Artieda A. Aguado-Jodar A. Ruiz-Torrejón M.G. Kvasz